In vivo studies have shown that FTO knockout in mouse NK cells prevents melanoma metastasis, whereas in vitro experiments have indicated that FTO-deficient human NK cells exhibit an enhanced anti-tumor response to leukemia, thereby providing a promising strategy for allogeneic NK cell therapy (128). This evidence concerns the gene FTO and leukemia.